Jump to main content
Jump to site search

Issue 8, 2013
Previous Article Next Article

Progress towards the development of SH2 domain inhibitors

Author affiliations

Abstract

Src homology 2 (SH2) domains are 100 amino acid modular units, which recognize and bind to tyrosyl-phosphorylated peptide sequences on their target proteins, and thereby mediate intracellular protein–protein interactions. This review summarizes the progress towards the development of synthetic agents that disrupt the function of the SH2 domains in different proteins as well as the clinical relevance of targeting a specific SH2 domain. Since 1986, SH2 domains have been identified in over 110 human proteins, including kinases, transcription factors, and adaptor proteins. A number of these proteins are over-activated in many diseases, including cancer, and their function is highly dependent on their SH2 domain. Thus, inhibition of a protein's function through disrupting that of its SH2 domain has emerged as a promising approach towards the development of novel therapeutic modalities. Although targeting the SH2 domain is a challenging task in molecular recognition, the progress reported here demonstrates the feasibility of such an approach.

Graphical abstract: Progress towards the development of SH2 domain inhibitors

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 01 Nov 2012 and first published on 11 Feb 2013


Article type: Review Article
DOI: 10.1039/C3CS35449K
Citation: Chem. Soc. Rev., 2013,42, 3337-3370
  •   Request permissions

    Progress towards the development of SH2 domain inhibitors

    D. Kraskouskaya, E. Duodu, C. C. Arpin and P. T. Gunning, Chem. Soc. Rev., 2013, 42, 3337
    DOI: 10.1039/C3CS35449K

Search articles by author